Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA3 | P42263 | 1/20 | 0.54 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.54 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548490 | 0.82 | GRIA3 (0.56) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL2733233 | 0.80 | GRIA3 (0.54) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| Hydrochloric Acid SCHEMBL562597 | 0.80 | GRIA3 (0.54) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL548652 | 0.80 | GRIA3 (0.54) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL2834465 | 0.79 | ADORA3 (0.61) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL2731867 | 0.76 | ADORA3 (0.50) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL13689278 | 0.76 | GAA (0.50) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL8237246 | 0.76 | GRIA3 (0.50) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL1420530 | 0.76 | ADORA3 (0.57) | GRIA3GRIA4ENPP2ADORA3ADORA2A | |
| SCHEMBL9731669 | 0.76 | ADORA3 (0.50) | GRIA3GRIA4ENPP2ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260056191-A1 | POLYMERS AND CONJUGATES COMPRISING THE SAME | VENTANA MEDICAL SYSTEMS, INC. (US) | 2026-02-26 | — | — | US | claimed |
| US-20240123045-A1 | NONAUTOLOGOUS MULTI-STRESSED CANCER CELLS AND USES THEREOF FOR VACCINATING AND TREATING CANCERS | BRENUS PHARMA (FR) | 2024-04-18 | — | — | US | claimed |
| US-11079372-B2 | Polymers and conjugates comprising the same | VENTANA MEDICAL SYSTEMS, INC. (US) | 2021-08-03 | — | — | US | claimed |
| EP-2686438-B1 | A METHOD OF ANALYZING CHROMOSOMAL TRANSLOCATIONS AND A SYSTEM THEREFOR | VENTANA MED SYST INC (US) | 2018-04-18 | — | — | EP | claimed |
| EP-3201628-A2 | POLYMERS AND CONJUGATES COMPRISING THE SAME | Ventana Medical Systems, Inc. (US) | 2017-08-09 | — | — | EP | claimed |
| US-20170205399-A1 | POLYMERS AND CONJUGATES COMPRISING THE SAME | VENTANA MEDICAL SYSTEMS, INC. | 2017-07-20 | — | — | US | claimed |
| US-9562259-B2 | Method of analyzing chromosomal inversions | VENTANA MEDICAL SYSTEMS, INC. (US) | 2017-02-07 | — | — | US | claimed |
| WO-2016050913-A2 | POLYMERS AND CONJUGATES COMPRISING THE SAME | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-04-07 | — | — | WO | claimed |
| CN-103534359-A | A method of analyzing chromosomal translocations and a system therefore | VENTANA MED SYST INC | 2014-01-22 | — | — | CN | claimed |
| EP-2539466-A1 | CYTOGENIC ANALYSIS OF METAPHASE CHROMOSOMES | Ventana Medical Systems, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| EP-1368323-B1 | PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2010-06-30 | — | — | EP | claimed |
| EP-1362033-B1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2007-04-04 | — | — | EP | claimed |
| US-6936616-B2 | Pyrimidine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | claimed |
| JP-2004518723-A | — | — | 2004-06-24 | — | — | JP | claimed |
| EP-1368323-A1 | PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | claimed |
| EP-1362033-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | Warner-Lambert Company LLC (US) | 2003-11-19 | — | — | EP | claimed |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | claimed |
| US-20020151555-A1 | Pyrimidine matrix metalloproteinase inhibitors | BARVIAN NICOLE CHANTEL (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002064568-A1 | PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
| WO-2002064571-A1 | PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260056191-A1 | POLYMERS AND CONJUGATES COMPRISING THE SAME | POLD1, POLL, INCENP | GRIA3 3674/4885GRIA4 2966/4885ENPP2 1307/4885 |
| US-20020161000-A1 | Pyridine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | GRIA3 1776/4885GRIA4 2522/4885ENPP2 1535/4885 |
| US-20020151555-A1 | Pyrimidine matrix metalloproteinase inhibitors | MMP13, MMP3, MMP11 | GRIA3 2640/4885GRIA4 3605/4885ENPP2 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.